TCS Launches Agentic AI Platform for Drug Development
Tata Consultancy Services (TCS) has launched TCS ADD™ AgentHub, an enterprise-ready AI platform designed to transform drug development by enabling the scaled use of agentic AI. This platform aims to address challenges in trust, governance, and scalability within the highly regulated pharmaceutical industry, particularly in clinical trials and pharmacovigilance. TCS ADD™ AgentHub provides a structured framework for AI agents to operate with defined roles, oversight, and auditability, facilitating custom AI agent hubs and deployment across clinical workflows. The platform has demonstrated significant efficiency gains, including up to 40% in clinical data management, up to 30% reduction in clinical study build effort, and up to 30% cost savings in safety case processing. It supports a Human + AI Operating Model, embedding AI agents into enterprise workflows while maintaining human oversight and decision-making.
Key Highlights
- TCS launches TCS ADD™ AgentHub for scaled agentic AI in drug development.
- Platform addresses regulatory, trust, and scalability challenges in pharma R&D.
- Demonstrated efficiency gains up to 40% in data management and 30% in study build.
- Enables Human + AI Operating Model with human oversight.
- Aims to accelerate drug development and improve patient safety.
Price Impact
More from TCS